Development of transcatheter heart valve therapy in the world in 2020_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

PAN Wenzhi , LONG Yuliang ,  ZHOU Daxin ,  GE Junbo

Department of Vasculocardiology, Zhongshan Hospital Fudan University, Shanghai, 200032, P.R.China;

Corresponding author：

ZHOU Daxin, Email: 1194180219@qq.com; GE Junbo, Email: ge.junbo2@zs-hospital.sh.cn

Keywords：

Transcatheter aortic valve therapy; transcatheter aortic valve replacement; interventional therapy; review

DOI：

10.7507/1007-4848.202012097

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In 2020, due to the impact of the novel coronavirus epidemic, the development of transcatheter heart valve therapy has been shown to slow down, but there are still many aspects worth noting. The indication of monoclonal antibody after transcatheter aortic valve replacement (TAVR) should be further clarified. Low surgical risk patients were included in TAVR relative indications. Mitraclip G4 was approved by CE. The indication of atrial septal occlusion after mitraclip should be further clarified. The technique of coaptation augmentation is expected to become a new method of mitral valve interventional repair. Tendyne transcatheter mitral valve was approved by European Union. Transcatheter tricuspid valve treatment equipments, TriClip and PASCAL obtained CE mark. TAVR technology is being popularized rapidly in China, and what’s more, balloon dilated valve Sapien 3 and new recyclable repositioning valve system-Venus plus have entered the domestic market. A number of mitral valve therapeutic instruments have appeared one after another, and China's first tricuspid valve lux has completed its FIM research. Finally, with the improvement of devices and technology in the future, interventional therapy of heart valve is expected to benefit more patients.

Citation： PAN Wenzhi, LONG Yuliang, ZHOU Daxin, GE Junbo. Development of transcatheter heart valve therapy in the world in 2020. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2021, 28(4): 371-375. doi: 10.7507/1007-4848.202012097 Copy

1.	Grover FL, Vemulapalli S, Carroll JD, et al. 2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. J Am Coll Cardiol, 2017, 69(10): 1215-1230.
2.	Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med, 2020, 383(15): 1447-1457.
3.	Abdul-Jawad Altisent O, Durand E, Muñoz-García AJ, et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv, 2016, 9(16): 1706-1717.
4.	Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med, 2020, 382(18): 1696-1707.
5.	Muller Moran HR, Eikelboom R, Lodewyks C. Two-year outcomes from the PARTNER 3 trial: Where do we stand? Curr Opin Cardiol, 2020 [Epub ahend of print].
6.	Writing Committee Members, Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: Executive Summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020 [Epub ahend of print].
7.	Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med, 2019, 380(18): 1695-1705.
8.	Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med, 2019, 380(18): 1706-1715.
9.	中国医师协会心血管内科医师分会结构性心脏病专业委员会. 经导管主动脉瓣置换术中国专家共识(2020更新版). 中国介入心脏病学杂志, 2020, 28(6): 301-309.
10.	Chakravarty T, Makar M, Patel D, et al. Transcatheter edge-to-edge mitral valve repair with the MitraClip G4 system. JACC Cardiovasc Interv, 2020, 13(20): 2402-2414.
11.	Praz F, Braun D, Unterhuber M, et al. Edge-to-edge mitral valve repair with extended clip arms: Early experience from a multicenter observational study. JACC Cardiovasc Interv, 2019, 12(14): 1356-1365.
12.	韩治伟, 周益锋, 郑金刚. 医源性房间隔缺损的研究进展. 中华心律失常学杂志, 2020, 24(5): 520-523.
13.	Morikawa T, Miyasaka M, Flint N, et al. Right-to-left shunt through iatrogenic atrial septal defect after MitraClip procedure. JACC Cardiovasc Interv, 2020, 13(13): 1544-1553.
14.	Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: The first 100 patients. J Am Coll Cardiol, 2019, 73(11): 1250-1260.
15.	Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol, 2018, 71(1): 12-21.
16.	Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet, 2019, 394(10213): 2002-2011.
17.	Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: A multicenter, observational, first-in-human experience. JACC Cardiovasc Interv, 2019, 12(24): 2488-2495.
18.	Pan W, Zhou D, Wu Y, et al. First-in-human results of a novel user-friendly transcatheter edge-to-edge mitral valve repair device. JACC Cardiovasc Interv, 2019, 12(23): 2441-2443.
19.	Lu FL, Ma Y, An Z, et al. First-in-man experience of transcatheter tricuspid valve replacement with LuX-Valve in high-risk tricuspid regurgitation patients. JACC Cardiovasc Interv, 2020, 13(13): 1614-1616.
20.	Song G, Pan W, Zhou D, et al. 2019 China Structure Week. Eur Heart J, 2020, 41(13): 1325-1327.

1. Grover FL, Vemulapalli S, Carroll JD, et al. 2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. J Am Coll Cardiol, 2017, 69(10): 1215-1230.
2. Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med, 2020, 383(15): 1447-1457.
3. Abdul-Jawad Altisent O, Durand E, Muñoz-García AJ, et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv, 2016, 9(16): 1706-1717.
4. Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med, 2020, 382(18): 1696-1707.
5. Muller Moran HR, Eikelboom R, Lodewyks C. Two-year outcomes from the PARTNER 3 trial: Where do we stand? Curr Opin Cardiol, 2020 [Epub ahend of print].
6. Writing Committee Members, Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: Executive Summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020 [Epub ahend of print].
7. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med, 2019, 380(18): 1695-1705.
8. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med, 2019, 380(18): 1706-1715.
9. 中国医师协会心血管内科医师分会结构性心脏病专业委员会. 经导管主动脉瓣置换术中国专家共识(2020更新版). 中国介入心脏病学杂志, 2020, 28(6): 301-309.
10. Chakravarty T, Makar M, Patel D, et al. Transcatheter edge-to-edge mitral valve repair with the MitraClip G4 system. JACC Cardiovasc Interv, 2020, 13(20): 2402-2414.
11. Praz F, Braun D, Unterhuber M, et al. Edge-to-edge mitral valve repair with extended clip arms: Early experience from a multicenter observational study. JACC Cardiovasc Interv, 2019, 12(14): 1356-1365.
12. 韩治伟, 周益锋, 郑金刚. 医源性房间隔缺损的研究进展. 中华心律失常学杂志, 2020, 24(5): 520-523.
13. Morikawa T, Miyasaka M, Flint N, et al. Right-to-left shunt through iatrogenic atrial septal defect after MitraClip procedure. JACC Cardiovasc Interv, 2020, 13(13): 1544-1553.
14. Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: The first 100 patients. J Am Coll Cardiol, 2019, 73(11): 1250-1260.
15. Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol, 2018, 71(1): 12-21.
16. Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet, 2019, 394(10213): 2002-2011.
17. Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: A multicenter, observational, first-in-human experience. JACC Cardiovasc Interv, 2019, 12(24): 2488-2495.
18. Pan W, Zhou D, Wu Y, et al. First-in-human results of a novel user-friendly transcatheter edge-to-edge mitral valve repair device. JACC Cardiovasc Interv, 2019, 12(23): 2441-2443.
19. Lu FL, Ma Y, An Z, et al. First-in-man experience of transcatheter tricuspid valve replacement with LuX-Valve in high-risk tricuspid regurgitation patients. JACC Cardiovasc Interv, 2020, 13(13): 1614-1616.
20. Song G, Pan W, Zhou D, et al. 2019 China Structure Week. Eur Heart J, 2020, 41(13): 1325-1327.

Next Article
Interpretation of the World Health Organization 2020 guidelines on physical activity and sedentary behaviour

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Development of transcatheter heart valve therapy in the world in 2020

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content